These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 18633105)
1. Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. Tan J; Yang S; Cai J; Guo J; Huang L; Wu Z; Chen J; Liao L Diabetes; 2008 Oct; 57(10):2666-71. PubMed ID: 18633105 [TBL] [Abstract][Full Text] [Related]
2. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Hirshberg B; Rother KI; Digon BJ; Lee J; Gaglia JL; Hines K; Read EJ; Chang R; Wood BJ; Harlan DM Diabetes Care; 2003 Dec; 26(12):3288-95. PubMed ID: 14633816 [TBL] [Abstract][Full Text] [Related]
3. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. Froud T; Baidal DA; Faradji R; Cure P; Mineo D; Selvaggi G; Kenyon NS; Ricordi C; Alejandro R Transplantation; 2008 Dec; 86(12):1695-701. PubMed ID: 19104407 [TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Kaufman DB; Leventhal JR; Gallon LG; Parker MA Am J Transplant; 2006 Feb; 6(2):331-9. PubMed ID: 16426317 [TBL] [Abstract][Full Text] [Related]
5. Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. Lehmann R; Weber M; Berthold P; Züllig R; Pfammatter T; Moritz W; Mädler K; Donath M; Ambühl P; Demartines N; Clavien And PA; Andreia Spinas G Am J Transplant; 2004 Jul; 4(7):1117-23. PubMed ID: 15196070 [TBL] [Abstract][Full Text] [Related]
6. Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression. Nijhoff MF; Engelse MA; Dubbeld J; Braat AE; Ringers J; Roelen DL; van Erkel AR; Spijker HS; Bouwsma H; van der Boog PJ; de Fijter JW; Rabelink TJ; de Koning EJ Am J Transplant; 2016 Jan; 16(1):246-53. PubMed ID: 26288226 [TBL] [Abstract][Full Text] [Related]
7. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Knechtle SJ; Pascual J; Bloom DD; Torrealba JR; Jankowska-Gan E; Burlingham WJ; Kwun J; Colvin RB; Seyfert-Margolis V; Bourcier K; Sollinger HW Am J Transplant; 2009 May; 9(5):1087-98. PubMed ID: 19344431 [TBL] [Abstract][Full Text] [Related]
8. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. Shapiro AM; Lakey JR; Ryan EA; Korbutt GS; Toth E; Warnock GL; Kneteman NM; Rajotte RV N Engl J Med; 2000 Jul; 343(4):230-8. PubMed ID: 10911004 [TBL] [Abstract][Full Text] [Related]
9. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. Uemura T; Ramprasad V; Matsushima K; Shike H; Valania T; Kwon O; Ghahramani N; Shah R; Farooq U; Khan A; Kadry Z Transplantation; 2011 Sep; 92(6):678-85. PubMed ID: 21841541 [TBL] [Abstract][Full Text] [Related]
10. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Tan HP; Kaczorowski DJ; Basu A; Khan A; McCauley J; Marcos A; Fung JJ; Starzl TE; Shapiro R Transplantation; 2004 Dec; 78(11):1683-8. PubMed ID: 15591960 [TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. Kaufman DB; Leventhal JR; Axelrod D; Gallon LG; Parker MA; Stuart FP Am J Transplant; 2005 Oct; 5(10):2539-48. PubMed ID: 16162205 [TBL] [Abstract][Full Text] [Related]
12. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Farney A; Sundberg A; Moore P; Hartmann E; Rogers J; Doares W; Jarrett A; Adams P; Stratta R Clin Transplant; 2008; 22(1):41-9. PubMed ID: 18217904 [TBL] [Abstract][Full Text] [Related]
13. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. Toso C; Baertschiger R; Morel P; Bosco D; Armanet M; Wojtusciszyn A; Badet L; Philippe J; Becker CD; Hadaya K; Majno P; Bühler L; Berney T; Am J Transplant; 2006 May; 6(5 Pt 1):1049-58. PubMed ID: 16611343 [TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Muthusamy AS; Vaidya AC; Sinha S; Roy D; Elker DE; Friend PJ Am J Transplant; 2008 Oct; 8(10):2126-31. PubMed ID: 18828772 [TBL] [Abstract][Full Text] [Related]
16. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Tan HP; Kaczorowski DJ; Basu A; Unruh M; McCauley J; Wu C; Donaldson J; Dvorchik I; Kayler L; Marcos A; Randhawa P; Smetanka C; Starzl TE; Shapiro R Am J Transplant; 2006 Oct; 6(10):2409-17. PubMed ID: 16889606 [TBL] [Abstract][Full Text] [Related]
17. Islet of Langerhans allogeneic transplantation at the University of Geneva in the steroid free era in islet after kidney and simultaneous islet-kidney transplantations. Berney T; Bucher P; Mathe Z; Andres A; Bosco D; Mage R; Toso C; Oberholzer J; Becker C; Philippe J; Bühler L; Morel P Transplant Proc; 2004 May; 36(4):1121-2. PubMed ID: 15194390 [TBL] [Abstract][Full Text] [Related]